LRRK2 PROTAC (ARV-102): From Target Degradation to Biomarker-Driven Trials LRRK2 PROTAC (ARV-102): From Target Degradation to Biomarker-Driven Trials Curator: Warren Peters, MD, MPH, FOMA Silo: Voice of Health – Research Edition Research Summary ARV-102 is a proteolysis-targeting chimera (PROTAC) that binds LRRK2 and recruits an E3 ligase, tagging the protein for degradation. Unlike traditional kinase… Continue reading New Approach in Parkinson’s
Author: Merwin
Removing a Problem Protein
A New Approach in Parkinson’s: Removing a Problem Protein (LRRK2) A New Approach in Parkinson’s: Removing a Problem Protein Silo: Voice of Health – Patient Edition What’s Being Studied Scientists are testing a new therapy called ARV-102. It helps cells identify and remove a protein called LRRK2 that may contribute to Parkinson’s. The first trial… Continue reading Removing a Problem Protein
What the GLP-1 Shift Means
Healthspan Is Becoming Real: What the GLP-1 Shift Means Healthspan Is Becoming Real: What the GLP-1 Shift Means At a leading aging research meeting, major drug makers described GLP-1 medicines as “longevity therapeutics.” That language shift matters: it opens the door to earlier prevention trials, better biomarkers, and treatments that aim to help us live… Continue reading What the GLP-1 Shift Means
Healthspan Is Becoming Real
Healthspan Is Becoming Real: What the GLP-1 Shift Means Healthspan Is Becoming Real: What the GLP-1 Shift Means At a leading aging research meeting, major drug makers described GLP-1 medicines as “longevity therapeutics.” That language shift matters: it opens the door to earlier prevention trials, better biomarkers, and treatments that aim to help us live… Continue reading Healthspan Is Becoming Real
Working Together for Better Alzheimer’s Care
Working Together for Better Alzheimer’s Care: The ADRC Team Approach Working Together for Better Alzheimer’s Care Source: Akter S, Bawa EM, Riccardi N, et al. Journal of Alzheimer’s Disease Reports. 2025;9. doi:10.1177/25424823251385902 Silo: Voice of Health (Patient Edition) Why “Team Science” Matters Alzheimer’s affects memory, independence, and families. No single expert can solve it alone.… Continue reading Working Together for Better Alzheimer’s Care
GLP-1 Trial Maintains Motor Function in Parkinson’s Disease
Citation: Athauda D et al., 2025, New England Journal of Medicine, DOI 10.1056/NEJMoa2306791Research Summary:A randomized double-blind Phase 2 trial evaluated lixisenatide, a GLP-1 receptor agonist, in 156 individuals Participants received lixisenatide or placebo over 12 months. The lixisenatide group maintained stable with a decline in the placebo group. Gastrointestinal effects were the most common adverse… Continue reading GLP-1 Trial Maintains Motor Function in Parkinson’s Disease
Harnessing Team Science
Team Science for Dementia: The ADRC Circular Loop (Discovery → Development → Delivery → Dissemination) Harnessing Team Science in Dementia Research: The ADRC Circular Loop Citation: Akter S, Bawa EM, Riccardi N, et al. Journal of Alzheimer’s Disease Reports. 2025;9. doi:10.1177/25424823251385902 Curator: Warren Peters, MD MPH FOMA • Silo: Voice of Health (Research Edition) SEO… Continue reading Harnessing Team Science
Brain Health Beyond Biology
Cognitive health during aging is not just about genes or willpower. It’s about where we’re born, live, learn, work, and age—the social determinants of health (SDOH)—and the policies that shape those conditions. Because social environments and access to resources differ widely, not everyone experiences healthy cognitive aging. This long-form guide synthesizes cutting-edge evidence on SDOH… Continue reading Brain Health Beyond Biology
Parkinson’s In Plain Language.
Overview Parkinson’s shows up differently for everyone. This quick read answers the five questions families ask first, with links you can use today. Keep it simple, repeatable, and share what you’re seeing with your care team. 1) Early signs? Tremor at rest, slowed movement, stiffness, small handwriting, and softer voice are common. Track when you… Continue reading Parkinson’s In Plain Language.
A Masterstroke in Corporate Diplomacy
Pfizer’s Strategic Deal with the Trump Administration: A Masterstroke in Corporate Diplomacy In a move that has sent ripples through the pharmaceutical and political landscapes, Pfizer has announced a landmark agreement with the Trump administration to lower drug prices and invest heavily in domestic manufacturing. This three-year agreement, which runs through the end of the… Continue reading A Masterstroke in Corporate Diplomacy